Sernova Biotherapeutics Inc
SVA.TO
TSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -8.69% | 46.60% | -11.57% | 33.69% | -10.14% |
| Total Depreciation and Amortization | -92.63% | -66.74% | 302.09% | 0.00% | -73.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -35.30% | 111.20% | -21.70% | -14.06% | 216.53% |
| Change in Net Operating Assets | -31.03% | -28.28% | 296.03% | -731.87% | -92.53% |
| Cash from Operations | -525.95% | 91.83% | 44.13% | 20.51% | -18.18% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | 314.29% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 314.29% | -- | -- | -- |
| Total Debt Issued | -- | -47.90% | -96.28% | -- | -- |
| Total Debt Repaid | -- | 66.50% | 53.12% | -1.88% | -1.19% |
| Issuance of Common Stock | 380.14% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 520.88% | -- | -- | -100.00% | 125.56% |
| Cash from Financing | 318.08% | 114.41% | -96.57% | 20,638.22% | -99.56% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 75.52% | 109.38% | -350.62% | 116.44% | -564.87% |